David Mountcastle Sells 5,829 Shares of Privia Health Group (NASDAQ:PRVA) Stock

Privia Health Group, Inc. (NASDAQ:PRVA) CFO David Mountcastle sold 5,829 shares of the company’s stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $22.84, for a total transaction of $133,134.36. Following the sale, the chief financial officer directly owned 161,903 shares in the company, valued at $3,697,864.52. This represents a 3.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

David Mountcastle also recently made the following trade(s):

• On Friday, March 6th, David Mountcastle sold 5,177 shares of Privia Health Group stock. The stock was sold at an average price of $23.15, for a total value of $119,847.55.
• On Thursday, February 26th, David Mountcastle sold 5,361 shares of Privia Health Group stock. The stock was sold at an average price of $25.00, for a total value of $134,025.00.
• On Friday, February 27th, David Mountcastle sold 7,697 shares of Privia Health Group stock. The shares were sold at an average price of $25.05, for a total value of $192,809.85.
• On Friday, December 12th, David Mountcastle sold 23,887 shares of Privia Health Group stock. The stock was sold at an average price of $25.03, for a total value of $597,891.61.

Privia Health Group Stock Performance

Shares of NASDAQ:PRVA opened at $22.07 on Thursday. The business has a fifty day moving average of $22.97 and a 200-day moving average of $23.60. Privia Health Group, Inc. has a twelve month low of $18.77 and a twelve month high of $26.51. The firm has a market cap of $2.73 billion, a PE ratio of 129.82, a price-to-earnings-growth ratio of 1.42 and a beta of 0.82.

Privia Health Group (NASDAQ:PRVA) last issued its quarterly earnings results on Thursday, February 26th. The company reported $0.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.21. The business had revenue of $541.17 million for the quarter, compared to the consensus estimate of $516.61 million. Privia Health Group had a net margin of 1.08% and a return on equity of 3.06%. The firm’s quarterly revenue was up 17.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.21 EPS. On average, analysts anticipate that Privia Health Group, Inc. will post 0.14 EPS for the current fiscal year.

Key Privia Health Group News

Here are the key news stories impacting Privia Health Group this week:

• Positive Sentiment: Fresh quarterly results showed an earnings and revenue beat: Q4 EPS $0.25 vs. consensus $0.04 and revenue $541.2M (vs. $516.6M est.), with revenue up ~17% YoY — evidence of durable top-line growth that supports the company’s longer-term growth story. Earnings & company page
• Positive Sentiment: Analyst sentiment remains constructive: multiple firms (JPMorgan, RBC, Wolfe, BMO) have issued Outperform/Overweight views and raised price targets (consensus ~ $31), providing upside vs. current levels. That analyst support can limit downside and attract buyer interest. Analyst notes
• Positive Sentiment: Institutional buying reported (e.g., RBC, AQR, Intech added shares recently) and very high institutional ownership (~94%) — institutional inflows can stabilize the stock and are a backstop for larger pullbacks. Institutional holdings
• Neutral Sentiment: Technical/valuation context: 50-day ~$23.00, 200-day ~$23.61, 52‑week range $18.77–$26.51; current multiples are elevated (P/E >100), so the stock is sensitive to execution and guidance. Chart & technicals
• Negative Sentiment: Insider selling by the CEO — Parth Mehrotra sold ~63,439 shares across March 6 and March 9 (aggregate proceeds ≈ $1.46M). Large CEO sales are often viewed negatively by the market even if done for non-firm reasons. CEO Form 4
• Negative Sentiment: CFO David Mountcastle sold 11,006 shares across March 6 and March 9 (~$253k), reducing his stake — additional insider sales from senior finance leadership adds to downward pressure. CFO Form 4
• Negative Sentiment: EVP Edward Fargis sold ~9,343 shares across the two dates (~$215k), trimming his position — multiple concurrent insider sales by the C-suite increases perceived selling pressure. EVP Form 4

Analysts Set New Price Targets

Several equities analysts have recently issued reports on PRVA shares. Jefferies Financial Group reaffirmed a “buy” rating and set a $32.00 price target on shares of Privia Health Group in a research note on Thursday, February 26th. Citigroup lowered their price objective on Privia Health Group from $34.00 to $32.00 and set a “buy” rating for the company in a research report on Tuesday, March 3rd. Stephens restated an “overweight” rating and set a $32.00 target price on shares of Privia Health Group in a research report on Thursday, December 4th. Truist Financial raised their target price on shares of Privia Health Group from $31.00 to $33.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Finally, Canaccord Genuity Group lifted their price target on shares of Privia Health Group from $34.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. Thirteen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $31.00.

Institutional Investors Weigh In On Privia Health Group

A number of institutional investors have recently made changes to their positions in the stock. Bayban bought a new stake in Privia Health Group in the fourth quarter valued at about $26,000. Hantz Financial Services Inc. boosted its holdings in Privia Health Group by 456.2% during the fourth quarter. Hantz Financial Services Inc. now owns 1,129 shares of the company’s stock worth $27,000 after buying an additional 926 shares during the last quarter. Global Retirement Partners LLC grew its position in shares of Privia Health Group by 579.8% during the 4th quarter. Global Retirement Partners LLC now owns 1,584 shares of the company’s stock worth $38,000 after buying an additional 1,351 shares during the period. Canada Pension Plan Investment Board grew its position in shares of Privia Health Group by 48.0% during the 2nd quarter. Canada Pension Plan Investment Board now owns 3,700 shares of the company’s stock worth $85,000 after buying an additional 1,200 shares during the period. Finally, Kestra Advisory Services LLC bought a new stake in shares of Privia Health Group in the 4th quarter valued at about $93,000. 94.48% of the stock is owned by institutional investors and hedge funds.

About Privia Health Group

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.